C3N-03063
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 62.85284052
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.550
- INTERFERON_ALPHA_RESPONSE+0.550
- G2M_CHECKPOINT+0.510
- INTERFERON_GAMMA_RESPONSE+0.480
- MYC_TARGETS_V1+0.470
- ALLOGRAFT_REJECTION+0.440
- IL6_JAK_STAT3_SIGNALING+0.390
- MYC_TARGETS_V2+0.350
- INFLAMMATORY_RESPONSE+0.280
- COMPLEMENT+0.270
Top 10 suppressed
- ESTROGEN_RESPONSE_EARLY-0.340
- CHOLESTEROL_HOMEOSTASIS-0.330
- BILE_ACID_METABOLISM-0.270
- MYOGENESIS-0.250
- P53_PATHWAY-0.220
- APICAL_SURFACE-0.210
- ESTROGEN_RESPONSE_LATE-0.210
- FATTY_ACID_METABOLISM-0.210
- WNT_BETA_CATENIN_SIGNALING-0.210
- HEME_METABOLISM-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-02152 | — | cohortA1 | 0.883 |
| 2 | BS_4QW2S1Q8 | high-grade glioma | — | 0.881 |
| 3 | TCGA-E2-A1AZ-01A-11R-A12P-07 | — | D | 0.868 |
| 4 | TCGA-ZF-AA58-01A-12R-A42T-07 | — | — | 0.836 |
| 5 | TCGA-AR-A1AR-01A-31R-A137-07 | — | D | 0.832 |
| 6 | TCGA-FD-A3B6-01A-21R-A20F-07 | — | — | 0.829 |
| 7 | 9eec558d-cc8f-4816-80a5-b6aac4cbb94e | — | — | 0.823 |
| 8 | TCGA-G2-A2EF-01A-12R-A18C-07 | — | — | 0.823 |
| 9 | TCGA-83-5908-01A-21R-2287-07 | — | cohortA1 | 0.821 |
| 10 | TCGA-ZF-AA54-01A-11R-A39I-07 | — | — | 0.819 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.550 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.550 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.510 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.480 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.470 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.440 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.390 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.350 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.280 | Idelalisib | — uncovered |
| COMPLEMENT | 0.270 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.270 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.260 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.240 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.230 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.220 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.210 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.210 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.180 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.170 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.140 | Inavolisib | — uncovered |